CBNT yields 1000000.00% · ABBV yields 3.12%● Live data
📍 CBNT pulled ahead of the other in Year 1
Combined, CBNT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBNT + ABBV for your $10,000?
C-Bond Systems, Inc., a nanotechnology company, owns, develops, manufactures, and sells patented C-Bond technology in the United Sates. The company's products include C-Bond NanoShield, a patented nanotechnology windshield glass strengthening and hydrophobic all-in-one performance system to improve windshield safety and performance; C-Bond Secure, a patented non-toxic water-based nanotechnology solution to improve the strength of architectural glass and performance properties of window film-to-glass products; and C-Bond BRS, a patented nanotechnology ballistic-resistant film system that increases the structural integrity of glass. It also distributes MB-10 and Vimoba disinfectant tablets to school facilities and buses, dealerships, global distribution network, and service providers, as well as the transportation detailing, automotive, trucking, RV, rental agency, service vehicles, mass transit, golf carts, aviation, train, and marine markets. The company was founded in 2013 and is headquartered in Houston, Texas.
Full CBNT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.